Premium
Ultra‐performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma
Author(s) -
Kalovidouris Madgalene,
Michalea Stavroula,
Robola Nikoleta,
Koutsopoulou Maria,
Panderi Irene
Publication year - 2006
Publication title -
rapid communications in mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 136
eISSN - 1097-0231
pISSN - 0951-4198
DOI - 10.1002/rcm.2693
Subject(s) - chemistry , lercanidipine , chromatography , selected reaction monitoring , analyte , electrospray ionization , formic acid , detection limit , high performance liquid chromatography , extraction (chemistry) , mass spectrometry , liquid chromatography–mass spectrometry , tandem mass spectrometry , analytical chemistry (journal) , medicine , blood pressure , radiology
A simple, sensitive and rapid ultra‐performance liquid chromatography/positive electrospray ionization tandem mass spectrometry (UPLC/ESI‐MS/MS) method has been developed and validated for the determination of lercanidipine in human plasma. Lercanidipine and the internal standard, nicardipine, were extracted from plasma by liquid‐liquid extraction using tert ‐butyl methyl ether as the extraction solvent. UPLC analysis was performed isocratically on an AcQuity UPLC™ BEH C 18 analytical column (2.1 × 50.0 mm i.d., particle size 1.7 µm). The mobile phase consisted of 70% acetonitrile in water containing 0.2% v/v formic acid and pumped at a flow rate of 0.30 mL/min. ESI in positive ion mode, with multiple reaction monitoring (MRM), was chosen for the detection of the analytes. The assay was linear over a concentration range of 0.05–30 ng/mL for lercanidipine with a limit of quantitation of 0.05 ng/mL. Quality control samples (0.05, 0.15, 15 and 25 ng/mL) in five replicates from five of analytical runs demonstrated intra‐assay precision (% CV ≤7.3%), inter‐assay precision (% CV ≤6.1%) and an overall accuracy (% relative error) of less than 6.2%. A run time of less than 1.0 min for each sample made it possible to analyze a large number of human plasma samples per day. The method can be used to quantify lercanidipine in human plasma covering a variety of pharmacokinetic or bioequivalence studies. Copyright © 2006 John Wiley & Sons, Ltd.